ArticleExperimental dermatology2013
Targeting ALDH1A1 to treat pigmentary disorders.
Article in Experimental dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Proteomic profiling of metabolizing enzymes and transporters in 2 layers of Caucasian human skin.Drug metabolism and disposition: the biological fate of chemicals · 2026Article
- Proteomics data in vitiligo: a scoping review.Frontiers in immunology · 2024Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Clinical disorders related to skin pigmentation include hypo- or hyperpigmentation. Because they are difficult to treat, new approaches to develop safe pigment modulatory agents are needed. In the March issue of the journal, Paterson et al. (Exp Dermatol, 22, 2013) determined which aldehyde dehydrogenase 1A1 (ALDH1A1) substrates and products regulate melanogenesis. The authors demonstrated that ALDH1A1 substrate 9-cis retinal and its corresponding product 9-cis retinoic acid potently induced the accumulation of MITF mRNA, tyrosinase mRNA and melanin. Despite depletion of ALDH1A1, there was observed decreased ability of 9-cis retinal but not 9-cis retinoic acid to stimulate melanogenesis, indicating that ALDH1A1 regulates melanogenesis by catalysing the conversion of 9-cis retinal to 9-cis retinoic acid. Additionally, potent ALDH1A1 inhibitor such as cyanamide or Angeli's salt significantly suppressed pigmentation in human skin cells. These findings provide new candidate agents for the treatment of hypo- or hyperpigmentation disorders, using novel pigmentation-modulatory agents that target ALDH1A1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.